Cancer test kit GENESEEQLITE™

oncologyfor precision medicineSNV

GeneseeqLite™ is a compact panel that targets major actionable solid tumor genes. It includes variants implicated in hereditary cancers (POLE and POLD1), genetic alterations seen in non-small cell lung cancer (ALK, ROS1, BRAF, c-MET, RET, NTRK, KRAS and HER2) and genetic predispositions to reproductive cancers (BRCA1/2). GeneseeqLite™, like its predecessors, GeneseeqPrime™ and GeneseeqPrime™HRD, detects DNA mismatch repair (MMR) and microsatellite instability (MSI) – hallmarks of a cell’s inability to repair errors during DNA replication. Detection of these genetic features is relevant for determining a patient’s prognosis and identifying effective cancer treatments. Coverage of critical exons and fusion-related introns in 196 known actionable genes found in solid tumors Detection of targetable gene alterations informs targeted therapy, immunotherapy, PARP inhibitors for personalized treatment strategy Detection of alterations in EGFR, BRAF, ALK, RET, ROS1, KRAS, ERBB2, MET and NTRK to inform targeted therapy Detection of somatic and germline BRCA1/2 and homologous recombination pathway gene alterations to inform PARP inhibitor therapy Detection of POLD1/POLE gene, microsatellite sites, and DNA mismatch repair (MMR) genes including MLH1, MSH2, MSH6, PMS2 to comprehensively evaluate the microsatellite instability (MSI) status ctDNA-based liquid biopsy to monitor disease progression and predict the risk of postoperative/post-treatment tumor recurrence and metastases Timely assessment of drug resistance and associated mechanisms to guide targeted therapy Hereditary cancer risk assessment for early intervention